CAR T-cell Therapy | Specialty

Dr. Chaudhary on History of CAR T-Cell Therapy

January 11th 2017

Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses the history of chimeric antigen receptor (CAR) T-cell therapy.

Expert Highlights Efficacy of KTE-C19 CAR T-Cell Therapy in Non-Hodgkin Lymphoma

January 6th 2017

KTE-C19, an investigational CAR T-cell therapy, recently demonstrated positive results for patients with chemorefractory aggressive non-Hodgkin lymphoma.

KTE-C19 Leads to High Response Rates in Refractory NHL

December 7th 2016

Almost 80% of patients with treatment-refractory non-Hodgkin lymphoma had objective responses following treatment with KTE-C19, a chimeric antigen receptor T-cell therapy targeting CD19.

CTL019 Highly Effective in Global Phase II ALL Study, FDA Submission Anticipated

December 4th 2016

The CAR T-cell therapy CTL019 demonstrated an 82% complete remission (CR) or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Anti-CD22 CAR T-Cell Salvage Therapy Succeeds in Pediatric ALL

December 4th 2016

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia, many of whom had prior anti-CD19 CAR T-cell therapy.

Anti-BCMA CAR T-Cell Therapy Approaches 80% Response in Myeloma

December 2nd 2016

An investigational anti-BCMA chimeric antigen receptor T-cell therapy demonstrated an objective response rate of 78% in patients with relapsed/refractory multiple myeloma.

CLL Landscape to Change Dramatically Over Next Decade

November 21st 2016

Standard treatment approaches for patients with chronic lymphocytic leukemia will continue to include fludarabine, cyclophosphamide, and rituximab and allogeneic stem cell transplantation.

From Hospice to Remission: Hopes Remain High for CAR Therapies

October 28th 2016

Patients with advanced lymphoid malignancies have had few treatment options, particularly those with extensive, refractory disease. Allogeneic or autologous hematopoietic stem cell transplantation has been one life-prolonging and potentially curative option for these patients, but these procedures are associated with various toxicities and are not appropriate for all patients, with older adults and those with great- er disease burden often excluded as candidates.

Expert Describes Importance of Classifying T-Cell Lymphomas

October 28th 2016

Novel agents being explored in the landscape of both peripheral and cutaneous T-cell lymphomas could lead to an expansion of treatment options for patients.

KTE-C19 Induces Complete Remissions in Phase II Lymphoma Study

September 27th 2016

Treatment with KTE-C19 demonstrated an objective response rate of 79% and a complete remission rate of 52% for patients with aggressive, chemorefractory non-Hodgkin's lymphoma.

Anti-CD19 CAR T-Cell Therapy Induces Significant Remission Rates in B-Cell ALL

September 19th 2016

Chimeric antigen receptor T-cell therapy targeting CD19 demonstrated a nearly 80% complete remission rate across relapsed/refractory B-cell acute lymphoblastic leukemia patients with multiple levels of disease burden.

New Agents Vie for Role in Multiple Myeloma

September 15th 2016

Despite multiple therapeutic advances in recent years, proteasome inhibitors remain a cornerstone of therapy for multiple myeloma, both newly diagnosed and relapsed and refractory disease.

CAR T-Cell Therapy Continues to Show Promise in Non-Hodgkin Lymphoma

September 13th 2016

Chimeric antigen receptor T-cells offer highly effective therapy for patients with minimal residual disease or bulky disease in both aggressive and indolent B-cell non-Hodgkin lymphomas.

The Future of Myeloma Research

July 27th 2016

Relapse Type and Monoclonal Antibody Choice in Multiple Myeloma

July 27th 2016

Sequencing Monoclonal Antibodies in Myeloma

July 27th 2016

Moving Beyond Medians

July 27th 2016

Novel Agents with Len-Dex in Multiple Myeloma

July 27th 2016

Goals of Therapy for Relapsed Myeloma

July 27th 2016

Treatment Goals Based on Relapse Type in Myeloma

July 27th 2016